203 related articles for article (PubMed ID: 10424367)
21. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.
Eriksson BI; Lassen MR;
Arch Intern Med; 2003 Jun; 163(11):1337-42. PubMed ID: 12796070
[TBL] [Abstract][Full Text] [Related]
22. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study.
Schellong SM; Gerlach HE; Tebbe U; Haas S; Melzer N; Abletshauser C; Sieder C; Bramlage P; Riess H; Bauersachs R
Thromb Res; 2011 Nov; 128(5):417-21. PubMed ID: 21658750
[TBL] [Abstract][Full Text] [Related]
23. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
Bell GK; Goldhaber SZ
Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group.
Hamulyák K; Lensing AW; van der Meer J; Smid WM; van Ooy A; Hoek JA
Thromb Haemost; 1995 Dec; 74(6):1428-31. PubMed ID: 8772214
[TBL] [Abstract][Full Text] [Related]
25. [The thromboprophylactic effect of low molecular weight heparin (Fragmin) in hip fracture surgery. A placebo controlled trial].
Jørgensen PS; Knudsen JB; Broeng L; Josephsen IL; Bjerregaard P; Hagen KK; Jørgensen PK; Tørholm C
Ugeskr Laeger; 1993 Mar; 155(10):706-8. PubMed ID: 8384388
[TBL] [Abstract][Full Text] [Related]
26. Deferment of objective assessment of deep vein thrombosis and pulmonary embolism without increased risk of thrombosis: a practical approach based on the pretest clinical model, D-dimer testing, and the use of low-molecular-weight heparins.
Siragusa S; Anastasio R; Porta C; Falaschi F; Pirrelli S; Palmieri P; Gamba G; Granzow K; Malato A; Minardi V; Tatoni P; Bressan MA; Mariani G
Arch Intern Med; 2004 Dec 13-27; 164(22):2477-82. PubMed ID: 15596639
[TBL] [Abstract][Full Text] [Related]
27. An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin Assessment Group.
Boneu B
Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S21-2. PubMed ID: 8180325
[TBL] [Abstract][Full Text] [Related]
28. Deep vein thrombosis prevention in joint arthroplasties: continuous enhanced circulation therapy vs low molecular weight heparin.
Gelfer Y; Tavor H; Oron A; Peer A; Halperin N; Robinson D
J Arthroplasty; 2006 Feb; 21(2):206-14. PubMed ID: 16520208
[TBL] [Abstract][Full Text] [Related]
29. Comparison of 3,000 and 5,000 IU aXa/day certoparin in the prevention of deep-vein thrombosis after total hip replacement.
Bramlage P; Michaelis HC; Melzer N
Thromb J; 2012 Jun; 10(1):10. PubMed ID: 22713698
[TBL] [Abstract][Full Text] [Related]
30. A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke.
Sandset PM; Dahl T; Stiris M; Rostad B; Scheel B; Abildgaard U
Semin Thromb Hemost; 1990 Oct; 16 Suppl():25-33. PubMed ID: 1962901
[TBL] [Abstract][Full Text] [Related]
31. [Subcutaneous small heparin doses for the prevention of thrombosis in general surgery and urology].
Rem J; Duckert F; Fridrich R; Gruber UF
Schweiz Med Wochenschr; 1975 Jun; 105(26):827-35. PubMed ID: 1215880
[TBL] [Abstract][Full Text] [Related]
32. Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization.
Lassen MR; Borris LC; Nakov RL
N Engl J Med; 2002 Sep; 347(10):726-30. PubMed ID: 12213943
[TBL] [Abstract][Full Text] [Related]
33. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
Ramacciotti E; Araújo GR; Lastoria S; Maffei FH; Karaoglan de Moura L; Michaelis W; Sandri JL; Dietrich-Neto F;
Thromb Res; 2004; 114(3):149-53. PubMed ID: 15342210
[TBL] [Abstract][Full Text] [Related]
34. The thromboprophylactic effect of a low-molecular-weight heparin (Fragmin) in hip fracture surgery. A placebo-controlled study.
Jørgensen PS; Knudsen JB; Broeng L; Josephsen L; Bjerregaard P; Hagen K; Jørgensen PK; Tørholm C
Clin Orthop Relat Res; 1992 May; (278):95-100. PubMed ID: 1314147
[TBL] [Abstract][Full Text] [Related]
35. Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine.
Haas S; Stemberger A; Fritsche HM; Welzel D; Wolf H; Lechner F; Blümel G
Arzneimittelforschung; 1987 Jul; 37(7):839-43. PubMed ID: 2823840
[TBL] [Abstract][Full Text] [Related]
36. Prevention of postoperative deep vein thrombosis in cancer patients. A randomized trial with low molecular weight heparin (CY 216).
Marassi A; Balzano G; Mari G; D'Angelo SV; Della Valle P; Di Carlo V; D'Angelo A
Int Surg; 1993; 78(2):166-70. PubMed ID: 8394842
[TBL] [Abstract][Full Text] [Related]
37. A dose ranging study to evaluate dermatan sulphate in preventing deep vein thrombosis following total hip arthroplasty.
Cohen AT; Phillips MJ; Edmondson RA; Skinner JA; Das SK; Cooper DJ; Thomas EM; Melissari E; Kakkar VV
Thromb Haemost; 1994 Dec; 72(6):793-8. PubMed ID: 7740443
[TBL] [Abstract][Full Text] [Related]
38. Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum).
Cosmi B; Filippini M; Campana F; Avruscio G; Ghirarduzzi A; Bucherini E; Camporese G; Imberti D; Legnani C; Palareti G;
Thromb Res; 2014 Feb; 133(2):196-202. PubMed ID: 24365043
[TBL] [Abstract][Full Text] [Related]
39. Low doses of heparin and heparin dihydergot in postoperative thromboprophylaxis in gynaecological patients.
Urlep-Salinović V; Jelatancev B; Gorisek B
Thromb Haemost; 1994 Jul; 72(1):16-20. PubMed ID: 7974365
[TBL] [Abstract][Full Text] [Related]
40. Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin).
Dahl OE; Andreassen G; Aspelin T; Müller C; Mathiesen P; Nyhus S; Abdelnoor M; Solhaug JH; Arnesen H
Thromb Haemost; 1997 Jan; 77(1):26-31. PubMed ID: 9031444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
